Flexion Therapeutics Announces Inclusion of ZILRETTA in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee

• AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids
  

BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee.¹

The AAOS guidelines reflect a moderate recommendation for the use of intra-articular (IA) corticosteroids for patients with symptomatic OA of the knee. The recommendation follows a review of data from 25 studies assessing IA corticosteroids. Included in its rationale is a differential analysis of extended-release intra-articular steroid, of which ZILRETTA is the only available product, versus immediate-release IA corticosteroids, where AAOS analyses demonstrated that it can, “be used over immediate-release corticosteroids to improve patient outcomes.”

“We are very pleased that the AAOS data review has determined that ZILRETTA can play a differentiated role in the treatment of OA knee pain,” said Michael Clayman, M.D., President and Chief Executive Officer of Flexion. “This supports our belief that ZILRETTA is an important option for the millions of people who confront OA knee pain every year.”

Andrew I. Spitzer, M.D., Professor of Orthopaedic Surgery, Clinical Chief, Department of Orthopaedic Surgery, Co-Director, Joint Replacement Program, Cedars-Sinai Department of Orthopaedic Surgery added, “I believe these guidelines acknowledge the quality of data surrounding the efficacy and safety of ZILRETTA and offer healthcare providers who treat patients with knee OA added confidence to further incorporate ZILRETTA into their clinical practice.”  

The AAOS guidelines serve as an educational tool to help guide clinical treatment decisions to improve the quality and effectiveness of care and were last revised in 2013.

Indication and Select Important Safety Information for ZILRETTA

Indication: ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.

Warnings and Precautions: